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Importance. Cutaneous and systemic plasmacytosis are rare conditions of unknown etiology with characteristic red-brown skin
lesions and a mature polyclonal plasma cell infiltrate within the dermis. Perineural plasma cell infiltrates may be a histologic clue
to the diagnosis of cutaneous plasmacytosis. Observations. Our patient had a five-year history of persistent reddish-brown plaques
on the neck and trunk without systemic symptoms. Histologic examination showed dermal perivascular and perineural plasma
cells with excess lambda light chain expression. Due to decreased quality of life caused by his skin lesions, he was placed on a
chemotherapeutic regimen with bortezomib. Conclusions and Relevance. The patient was diagnosed with cutaneous plasmacytosis
based on classic histopathology results with a recently characterized pattern of perineural involvement. Bortezomib therapy was
initiated to manage his skin eruption, which has not been previously described as a treatment for this chronic condition.
1. Introduction
Cutaneous and systemic plasmacytosis are rare, lympho-
plasmacytic disorders characterized by red-brown poorly
circumscribed plaques and nodules occurring mainly on
the trunk primarily in patients of Japanese descent [1, 2].
The disease can be accompanied by fever, lymphadenopathy,
anemia, and a polyclonal hypergammaglobulinemia [2, 3].
The characteristic histopathology is dermal perivascular infil-
trates of mature polyclonal plasma cells [2, 4]. Herein we
present a Hispanic patient with chronic red-brown macules
and plaques on the trunk where these distinctive biopsy
findings supported the diagnosis of cutaneous plasmacytosis.
We discuss the classical histopathologic features of cutaneous
plasmacytosis and evidence for cutaneous-only involvement
of this condition.
2. Case
A 39-year-old Hispanic man presented with a five-year
history of persistent red plaques on his neck and a two-
year history of similar lesions that had spread to his trunk,
sparing the upper and lower extremities. His past medical
history included untreated latent tuberculosis infection and
allergic rhinitis. Clinical examination revealed brownish-
red macules and mildly indurated plaques on his trunk
(Figure 1) and pink-to-violaceous plaques with fine scale on
his neck. He was afebrile and had no lymphadenopathy.
Laboratory examination showed normal complete blood
count, serum protein, and erythrocyte sedimentation rate,
no monoclonal protein on immunofixation, and hyperim-
munoglobulin (Ig) E (199KU/L—normal: <25KU/L). The
serum level of interleukin-(IL-) 6 was normal and antinuclear
antibodies were negative. Free kappa and lambda chains
and the kappa: lambda ratio were normal. Urinalysis was
without blood or protein with no measurable Bence Jones
protein in the urine. Human immunodeficiency virus, rapid
plasma reagin, and Borrelia burgdorferi IgM were nega-
tive. Positron emission tomography/computed tomography
(PET/CT) showed no evidence of fluorodeoxyglucose (FDG)
avid cutaneous lesions or other areas of active disease.
3. Histology, Molecular Studies,
and Therapeutic Trials
Skin biopsies from the abdomen, neck/shoulder, flank, and
cervical region were obtained. The distinctive feature was a
Hindawi Publishing Corporation
Case Reports in Dermatological Medicine
Volume 2014, Article ID 840845, 4 pages
http://dx.doi.org/10.1155/2014/840845
2 Case Reports in Dermatological Medicine
(a) (b)
Figure 1: (a)The patient presentedwith brownish-redmacules andmildly indurated plaques on his abdomen. (b) Similar lesions were present
on his chest.
superficial and deep perivascular and perineural dermatitis
with prominent plasma cells (Figures 2 and 3). The plasma
cells were highlighted by IgG but negative for IgG4. There
were evidence of B-cell clonality by PCR gene rearrangement
analysis (two of two specimens) and evidence of slight lambda
excess by immunohistochemistry and in situ hybridization.
Other small B cells were highlighted byCD20 but negative for
Bcl-6. Small CD3-positive T cells were intermixed with the
plasma cells. CD117 marked background levels of mast cells.
Immunohistochemical staining for T. pallidum was negative.
PAS, Fite, and Warthin-Starry stains were negative. Tissue
cultures for bacteria, mycobacteria, viruses, and fungi were
negative. These skin biopsies were reviewed by our insti-
tution’s dermatopathologists and hematopathologists and
subsequently in consultation at the National Institutes of
Health. Bone marrow aspirate demonstrated normocellular
marrow with mildly increased numbers of plasma cells seen
by CD138 and a minute kappa dominant plasma cell popu-
lation detected by flow cytometry. Occasional small groups
of plasma cells were seen which were predominantly associ-
ated with vessels. This distribution with only 5-6% plasma
cells in the absence of atypia favored a reactive etiology.
Chromosome analysis showed a normal male chromosome
complement.
After evaluation by hematology and oncology, the patient
was prescribed a one-month course of doxycycline to elimi-
nate a possible nidus of infection with subsequent worsening
of his cutaneous plaques on this therapy. He was later
treated with a three-week course of clobetasol ointment with
continued worsening. Since this patient did not tolerate a
trial of clobetasol ointment and there is not currently an
FDA-approved pharmacologic therapy for cutaneous plas-
macytosis, an alternative therapy was investigated. After
extrapolating from cutaneous T- and B-cell malignancy data
as well as other plasma cell disorder therapies, the decision
was made to start bortezomib. He subsequently was put
on subcutaneous bortezomib 1.3mg/m2. His chemotherapy
regimen included twice weekly injections over two weeks for
Figure 2: Abdominal biopsy highlighting dermal plasmacytes,
which were evident in biopsies of the patient’s abdomen, flank, and
neck (hematoxylin & eosin stain; original magnification: ×40).
Figure 3: Abdominal biopsy was notable for perineural plasmacytes
(hematoxylin & eosin stain; original magnification: ×600).
a total of four treatments per cycle, which he tolerated with
mild nausea and myalgias. The skin lesions did not progress
and he did not develop any new eruptions after two cycles of
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therapy; however, his rash showed partial regression after a
total of eight treatments.
4. Discussion
Cutaneous plasmacytosis is a disorder of unknown etiology,
which was first described by Yashiro as a “kind of plasma-
cytosis” and later redefined by Kitamura et al. as “cutaneous
plasmacytosis” [1, 5]. Whether pure cutaneous plasmacytosis
is a condition distinct from systemic involvement has been
debated. It has been proposed that asymptomatic patients
with manifestations of cutaneous plasmacytosis may have
systemic involvement [6, 7]. Thus, these patients may war-
rant additional work-up, such as a superficial lymph node
biopsy, to exclude the disorder of cutaneous and systemic
plasmacytosis. Similar to prior case reports of cutaneous
plasmacytosis, our patient had no palpable lymphadenopathy
to suggest systemic involvement and PET/CT with FDG did
not highlight any extracutaneous activity. Further evaluation
by bone marrow biopsy revealed slightly increased plasma
cells, which was thought to be reactive. It was determined
that lymph node biopsy for histopathologic examination to
rule out this largely benign, chronic, and indolent condition
was not clinically warranted in this patient given the imaging
and bone marrow biopsy results and selection of aggressive
treatment.
Histopathology characteristically demonstrates a mod-
erately dense, superficial, and deep perivascular and peri-
adnexal infiltrate of plasma cells without atypia [3, 4]. The
plasma cells are typically polyclonal andmature. In aminority
of cases, accompanying small reactive germinal centers are
found [2, 8]. Recently, focal infiltrates of perineural plasma
cells were described in six patients with cutaneous plasma-
cytosis [8]. Intraneural plasma cells were also observed in a
subset of these patients. In biopsies from our patient, marked
perivascular and perineural plasmacytosis in the dermis was
present. After no infectious etiologies were identified, this
patient with normal IL-6 and gammaglobulin levels was
diagnosed with cutaneous plasmacytosis by clinical correla-
tion between the skin lesions and confirmatory histopathol-
ogy. This case adds to the spectrum of histopathologic
presentations that cutaneous plasmacytosis may take on in
the absence of systemic signs and characteristic laboratory
findings.
Although this condition is primarily described inmiddle-
aged patients of Japanese descent, there have been case
reports of cutaneous plasmacytosis occurring in patients
of other Asian ethnicities and Caucasian descent [7]. Our
patient is the first Hispanic individual reported to have
cutaneous plasmacytosis.
Cutaneous plasmacytosis typically follows a benign clin-
ical course, which does not require treatment; however,
decreased quality of life due to the appearance of the lesions
was a significant concern for this patient. Various treatment
approaches have been tried to induce clinical remission. Top-
ical and systemic corticosteroids, topical tacrolimus, antibi-
otics, and systemic chemotherapy have produced variable
long-term clinical results [3, 9]. Treatment with intralesional
steroids, combination prednisone and cyclophosphamide,
photodynamic therapy with long-pulse ruby laser, psoralen-
UVA, and topical pimecrolimus have reportedly improved
skin lesions of cutaneous plasmacytosis [10–14].
Bortezomib is FDA-approved for the treatment of mul-
tiple myeloma and mantle cell lymphoma in patients who
have received at least one prior therapy [15]. This chemother-
apeutic agent acts by inhibiting the 26S proteasome, which
prevents selective proteolysis and can lead to cell death.
The pathophysiology of cutaneous plasmacytosis has not
yet been elucidated and it is uncertain whether therapy
that targets other plasma cell malignancies will be effective
for plasmacytosis. This patient was placed on a regimen of
twice weekly subcutaneous bortezomib followed by a 10-day
rest period. After two cycles, the patient developed no new
lesions and the persistent plaques had evidence of regression.
Additional cycles of chemotherapy are planned and longer-
term follow-up is needed. The patient experienced a mild
adverse reaction during the course of therapy.
5. Conclusion
Cutaneous and systemic plasmacytosis are largely benign
conditionswith unknown pathophysiology that occurmainly
in Japanese patients and can have a wide range of clinical and
histopathologic presentations. We report a case of cutaneous
plasmacytosis with distinctive perineural involvement, a
histopathologic feature that may aid in the diagnosis of this
disorder when used with clinical correlation. This is also the
first case of a Hispanic patient presenting with cutaneous
plasmacytosis. Further, this patient was treated with borte-
zomib with partial improvement after two cycles of therapy.
Additional long-term studies are needed to determine the
potential efficacy of targeted chemotherapeutic medications
for the management of cutaneous plasmacytosis.
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